Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Novastan: Began a 750-patient Phase II trial. The primary end point is a composite of death and adverse cardiac events; secondary end point is patency after 90

Texas Biotechnology Corp. (TXB), Houston
Product:

Read the full 69 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE